Delta4 expands Team and tackles new indications

Following our Financing in March 2021 and our move into new premises in July 2021 we are continuing to expand our footprint and our capabilities. To that effect I am happy to announce that Samuel Gerner has joined the team as Data Scientist. Samuel will finish his PhD in the next few months and will add his experience and knowledge to our excellent team.

Samuel is a bioinformatician with a strong biological background, having studied Molecular Biotechnology and Bioinformatics at the FH Campus Wien together with his PhD studies under Prof. Thomas Rattei at the Division of Computational Systems Biology (CUBE) at the University of Vienna.

His extensive experience with biological as well as bioinformatic aspects of research projects will further push our capabilities and we are looking forward to tackle the next challenges together.

Furthermore, over the next few months Delta4 will start to work on additional indications, beginning with another nephrological disease and an autoimmune illness, followed by others in the neurological and gastro-enterological fields.

Asset development by Delta4 is driven by our proprietary platform technology as well as straight-forward selection criteria to identify the most promising therapeutic areas for drug repurposing. Most of the new indications are orphan / rare diseases, as this area continues to be a natural field to successfully deploy our unique repurposing technology.

Please feel free to get in touch via e-mail (office@delta4.ai) if you are interested in either an existing Delta4 project, or would like to discuss a potential cooperation / service project.